Phase III SYNERGY trial: Docetaxel +/- custirsen and overall survival in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and poor prognosis (Poster, Abstract #5009)•Poster: Saturday, May 30, 1:15 PM CDT – S Hall A
•Poster Discussion: Saturday, May 30, 4:45 PM CDT - E Arie Crown Theater
•First-line randomized phase II study of gemcitabine/cisplatin plus apatorsen or placebo in patients with advanced bladder cancer: The International Borealis-1 trial (Oral Session, Abstract #4503)•Monday, June 1, 9:45 AM CDT - E Arie Crown Theater
•The Borealis-2™ clinical trial: A randomized phase 2 study of OGX-427 (Apatorsen) plus docetaxel versus docetaxel alone in relapsed/refractory metastatic urothelial cancer (Poster, Abstract #TPS4577)•Monday June 1, 1:15 PM CDT – S Hall A, Board #247b
•Addition of apatorsen, an inhibitor of Hsp27, to first-line gemcitabine/carboplatin in advanced squamous cell lung cancer: Design of the Cedar™ study (Poster, Abstract #TPS8111)•Monday June 1, 8:00 AM CDT – S Hall A, Board #431b
Look who the study is designed for...and they didn't stop out for safety...it's going to pop nicely!
You are very correct about the offer....
.... or the markets in Europe are going to mess the bed.
I do believe you could be right....or close. The fed is not raising...they will use the right words to
calm the market. I started 10k @ 1.94....I maybe a little early.